External Advisory Board

The OHSU Knight Cardiovascular Institute has established an external advisory board to help guide our growth and development. It is comprised of industry experts, renowned colleagues from other institutions and regional leaders.

Douglas E. Vaughan, M.D., is the Irving S. Cutter Professor of Medicine and chairman of the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago. He also serves as physician-in-chief of Northwestern Memorial Hospital.

Prior to moving to Northwestern in 2008, he was professor of medicine and Pharmacology, C. Sidney Burwell Professor of Medicine, chief, Division of Cardiovascular Medicine, and physician-in-chief of the Vanderbilt Heart and Vascular Institute at Vanderbilt University Medical Center in Nashville, Tennessee.

Dr. Vaughan earned his medical degree from the University of Texas Southwestern Medical School and trained in internal medicine at Parkland Memorial Hospital, Dallas, where he was also chief medical resident. He trained in cardiology as a fellow at Brigham and Women’s Hospital, Harvard Medical School, and completed additional postdoctoral training at the Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

Dr. Vaughan is a fellow of the American College of Cardiology and the Councils for High Blood Pressure Research and Atherosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists. His research program includes basic, translational and clinical research focused on the role of the plasminogen activator system in cardiovascular disease.
Joseph Loscalzo, M.D., Ph.D. is Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, chairman of the Department of Medicine, and physician-in-chief at Brigham and Women’s Hospital.

Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as resident and chief resident in medicine and fellow in cardiovascular medicine.

After completing his training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of associate professor of medicine, chief of cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as chief of cardiology and, in 1997, Wade Professor and Chair of Medicine, professor of biochemistry, and director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005.

Dr. Loscalzo is recognized as an outstanding cardiovascular scientist, clinician and teacher. He has received many awards, including the Clinician-Scientist Award, the Distinguished Scientist Award, the Research Achievement Award, and the Paul Dudley White Award from the American Heart Association; a Research Career Development Award, a Specialized Center of Research in Ischemic Heart Disease Award, and a MERIT Award from the National Institutes of Health; the George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital, and Educator of the Year Award in Clinical Medicine from Boston University; the Glaxo Cardiovascular Research Award, and the Outstanding Investigator Prize from the International Society for Heart Research; and election to the American Society for Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the National Academy of Sciences.

He has served on several NIH study sections and editorial boards, and has chaired the Gordon Conference on Thrombolysis. He served as an associate editor of the New England Journal of Medicine for nine years, chair of the Cardiovascular Board of the American Board of Internal Medicine, chair of the Research Committee of the American Heart Association, chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in the Cardiovascular Sciences, and chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health.

He is currently editor-in-chief of Circulation, a senior editor of Harrison’s Principles of Internal Medicine, a member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a member of the Council of Councils of the National Institutes of Health.
Dr. Loscalzo has been a visiting professor at many institutions, holds two honorary degrees, has authored or co-authored more than 500 scientific publications, has authored or edited 23 books, and holds 27 patents for his work in the field of nitric oxide. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis and atherosclerosis over the past twenty-five years.

---

Michael Mack, M.D. has practiced cardiothoracic surgery in Dallas, Texas since 1982. He is board-certified in internal medicine, general surgery and thoracic surgery and is currently the director of cardiovascular surgery for Baylor Scott & White Health, chair of the Baylor Scott & White Health Cardiovascular Governance Council and director of cardiovascular research at The Heart Hospital Baylor Plano. He also co-founded and is Chair of the Board of Cardiopulmonary Research Science and Technology Institute (CRSTI).

Dr. Mack has over 400 peer reviewed medical publications. He was president of the Society of Thoracic Surgeons (STS) 2011 and is past president of the Thoracic Surgery Foundation for Research and Education (TSFRE) 2009-2011, the Southern Thoracic Surgical Association (STSA) 2009 and the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2000.

He has served on the Board of Directors of the STS, is currently on the Board of Directors of CTSNet, and is a member of the American College of Cardiology Foundation (ACCF) Board of Trustees and the ACC Interventional Scientific Council. He is an honorary fellow of the German Society for Thoracic and Cardiovascular Surgery and the Indian Association of Cardiothoracic Surgery. He was the first chair of the STS/ACCF National Transcatheter Valve Therapy (TVT) Registry Steering Committee and is the liaison to the TVT Registry from the ACCF National Cardiac Data Registry (NCDR) Management Board and is on the Steering Committee of the Cardiothoracic Surgery Network (CTSN) of the NIH. He is a member of the FDA MDEpiNet Advisory Committee, the NCDR Management Board and the Brookings Institute National Medical Device Postmarket Surveillance System Planning Board.

---

Omar Ishrak has served as chairman and chief executive officer of Medtronic since June 2011.

Medtronic is the world’s leading medical technology company, with more than $16 billion in annual revenue, and operations reaching more than 120 countries worldwide. Medtronic provides therapies that are used to treat a wide range of conditions, including cardiac and vascular diseases, diabetes, neurological and spinal conditions, and more. The Medtronic Mission is to alleviate pain, restore health and extend life for millions of people around the world.

Ishrak joined Medtronic from General Electric Company, where he spent 16 years, most recently as president and CEO of GE Healthcare Systems, a
$12 billion division of GE Healthcare, with a broad portfolio of diagnostic, imaging, patient monitoring and life support systems. Omar also served as an officer and a senior vice president of GE.

Earlier in his career, Ishrak amassed 13 years of technology development and business management experience, holding leadership positions at Diasonics/Vingmed, and various product development and engineering positions at Philips Ultrasound.

He grew up in Bangladesh, earned a Bachelor of Science degree and Ph.D. in electrical engineering from the University of London, King’s College.

Ishrak is a member of the Board of Trustees of the Asia Society and is also on the Health Leadership Council of the Save the Children Foundation.

Peter O. Kohler, M.D., is vice chancellor of the University of Arkansas for Medical Sciences Northwest in Fayetteville and is guiding the medical sciences campus through its first expansion. He is also president emeritus of Oregon Health & Science University in Portland.

He is active in health policy, research and education at the national level and noted for his advocacy for increased access to health care and quality of life for underserved populations.

Dr. Kohler is a graduate of the University of Virginia and Duke Medical School. After postgraduate training at Duke and Georgetown, he began his medical career at the National Institutes of Health. He then went to Baylor College of Medicine where he served as professor of medicine and chief of endocrinology.

In 1977, Dr. Kohler became chairman of medicine at the University of Arkansas for Medical Sciences. There as chair and later interim dean, he became an active proponent of the Area Health Education Center program as a way of improving access to health care in underserved areas. Later, as dean of the University of Texas Medical School in San Antonio, he initiated development of an AHEC program in the Rio Grande Valley.

Dr. Kohler served as president of Oregon Health & Science University for over 18 years from 1988 to 2006. He helped develop an AHEC program in that state to increase the number of generalists being trained.

He has served as chair of the Oregon Health Council. He also chaired the NIH Endocrinology Study Section and the NICHD Board of Scientific Counselors. In 1995, Dr. Kohler led OHSU in a successful effort to establish itself as a free-standing public benefit corporation. He was elected to the Institute of Medicine and has served on the IOM Task Force on Telemedicine and chaired the IOM Committee on Quality in Long-term Care.

Dr. Kohler and his wife, Judy, have four children and eight grandchildren.
Raymond Preston Davis, also known as Ray, has been the CEO and president of Umpqua Holdings Corporation since 1999. Davis has also been the CEO of Umpqua Private Bank (also known as Umpqua Bank) a subsidiary of Umpqua Holdings Corp. since November, 2002 and as its president since March 2003.

He served as the chief financial officer of Umpqua Holdings Corp. Previously, Davis served as the chief executive officer and president of Umpqua Bank from June 1994 to December 2000. He joined Umpqua Bank in 1994.

Previously, he served as the president of US Banking Alliance in Atlanta, Georgia, a bank consulting firm. Davis has more than 30 years experience in banking and banking-related industries. He serves as the chairman of Umpqua Investments Inc. Asset Management Arm. He has three years experience as a certified public accountant. He has been a director of Umpqua Holdings Corporation since 1999 and Umpqua Bank since June 1994. Davis holds a bachelor’s degree from the University of Nevada, Reno.

Peter Lawrence, M.D. has actively participated in numerous regional and national professional organizations such as the Association for Surgical Education (president 1984-1985), Rocky Mountain Vascular Surgery Society (president 1989-1990), Western Vascular Society (president 1999-2000), Society for Clinical Vascular Surgery (president 2004-2005), National Board of Medical Examiners, American Surgical Association and the Society for Vascular Surgery. He is the president-elect (2012-2013) and will be president (2014-2015) of the Society for Vascular Surgery, the largest society in the world devoted to the management of vascular disease. He has also served the American Board of Surgery by writing the qualifying and certifying exam for surgeons.

Dr. Lawrence graduated from Dartmouth College and was awarded his M.D. degree with honors from Harvard Medical School. His surgical residency and vascular fellowship were done at Columbia-Presbyterian Medical Center in New York City.

In 1978 he joined the faculty at the University of Utah where he served as chief of surgery at the Veterans Administration Hospital, chair of the Division of Vascular Surgery, and president of the Medical Staff.

He moved to UC Irvine in 1998 to become the associate dean for clinical affairs, vice president for specialty services, and professor of surgery. In 2003 he moved to UCLA to become the Wiley Barker Chief of Vascular Surgery and director of the Gonda Vascular Center, as well as the Bergman Chair in Vascular Research.

He has published over 150 articles, editorials and book chapters. His research interests are related to aneurysms, limb salvage and venous disease. He has received National Institute of Health and Department of Defense funding for his research.
In addition to his subspecialty of Vascular Surgery, Dr. Lawrence has written two textbooks of surgery, Essentials of General Surgery and Essentials of Surgical Specialties, which are used at more than 70 percent of medical schools in their student education programs. He has been on the editorial boards of the Journal of Vascular Surgery, Vascular and Endovascular Surgery, Perspectives in Vascular Surgery, and Contemporary Surgery, as well as being a selective reviewer for seven other journals. He is currently editor of special features for the Journal of Vascular Surgery.

Ralph G. Quinsey has been the president and chief executive officer of Triquint Semiconductor, Inc. since joining it in July 2002. Quinsey served as vice president and general manager of the Analog Division of ON Semiconductor Corporation from September 1999 to January 2002.

From 1979 to September 1999, Quinsey was employed by Motorola, Inc. in various positions, including most recently as vice president and general manager for the RF/IF Circuits Division. He is a distinguished 30-year semiconductor veteran, having held leadership positions in several major technology companies.

He has been an executive director of Triquint Semiconductor, Inc. since July 2002. He has been a director of Volterra Semiconductor Corporation since January 21, 2011. Mr. Quinsey holds a Bachelor of Science degree in electrical engineering from Marquette University.

When the Portland State University (PSU) community selected Wim Wiewel in 2008 to be its eighth president, the institution renewed its promise to be an active partner in shaping Portland’s future — to fulfilling its motto: “Let Knowledge Serve the City.” With such publications to his credit as Global Universities and Urban Development (2008), The University as Urban Developer (2005), and Partnerships for Smart Growth (2005), Dr. Wiewel’s deep theoretical and practical knowledge of the relationship between universities and the communities they serve have made him the perfect “fit” for PSU.

Wim Wiewel holds degrees in sociology and urban planning from the University of Amsterdam and a Ph.D. in sociology from Northwestern University. Prior to coming to Portland State, he was provost and senior vice president of academic affairs at the University of Baltimore, where he led efforts to broaden the university’s role in the city’s revitalization.

Previously, Dr. Wiewel served as dean of the College of Business Administration and the College of Urban Planning and Public Affairs of the University of Illinois at Chicago, where he helped establish the Great Cities Program and the Center for Urban Economic Development. Besides the aforementioned books — and other books — he has authored dozens of articles in such publications as Economic Geography and the Journal of the American Planning Association.
Since joining PSU, Dr. Wiewel has focused his presidency — and the continuing development of the university — on five guiding themes: providing civic leadership through partnerships; improving student success; achieving global excellence; enhancing educational opportunity; and expanding resources to improve effectiveness.

Despite the financial crisis that hit hardest during the first year of his presidency, PSU has achieved great things on his watch. For example, PSU is now the largest and most diverse university in the state. Retention and graduation rates have increased every year, while funded research has gone up 50 percent, and fundraising has more than doubled. The university's business accelerator has been very effective in fostering new businesses and creating new jobs and this year, PSU launched reTHink: a campus-wide effort to update the way the university fosters student success.

President Wiewel’s leadership has not gone unnoticed, and since his arrival at PSU he has received the inaugural Presidential Award from the U.S. Green Building Council’s Center for Green Schools as well as the Leadership Award from the Council for the Advancement and Support of Higher Education. He has served as chair of the Coalition of Urban Serving Universities and is currently the chair of the American College and University Presidents Climate Commitment, as well as a board member of many other local and national organizations. Wim Wiewel is married to the architect Alice Wiewel and together they have four children.

Luiz Belardinelli, M.D. is the Chief Medical Officer of InCarda Therapeutics, Inc., located in California. The first 24 years of Dr. his professional career were spent in academia — first at the University of Virginia (1975) and then at the University of Florida (1988). He left academia in 2000 to work in the biopharmaceutical industry. In June 2016, Dr. Belardinelli became the chief medical officer of InCarda Therapeutics, a biotech company focused on developing cardiovascular therapies delivered via oral inhalation. Prior to that, he was a senior vice president at Gilead, heading the cardiovascular therapeutic area following the acquisition of CV Therapeutics in April 2009. At CV Therapeutics, Dr. Belardinelli was the senior vice president for Clinical Research & Pharmacology and Translational Biomedical Research from 1999 to 2009.

Dr. Belardinelli received his M.D. degree from the Medical Catholic School of Porto Alegre, Brazil, in 1975, and he completed a four-year postdoctoral research fellowship in the Department of Physiology at the University of Virginia. Subsequent academic appointments included assistant and associate professor of medicine, Division of Cardiology, University of Virginia (1980–1988), and professor of medicine (cardiology) and pharmacology as an Eminent Scholar of Cardiovascular Research at the University of Florida (1988–1999). Dr. Belardinelli is a recognized expert on adenosine physiology and pharmacology, cardiac electrophysiology, the role of the cardiac late sodium current in the regulation of intracellular Na+ and Ca2+ homeostasis, and cardiac arrhythmias. He has over 350 basic and clinical publications, and
more than 125 U.S. patents for various inventions. Dr. Belardinelli played a key role in the development and approval for human uses of Adenocard, Lexiscan and Ranexa. While at Gilead Sciences, he initiated the development of the first late sodium current inhibitor, Eleclazine, for the treatment of patients with LQT3 syndrome. He has received several awards, including “Inventor of the Year” from the Alumni Association of the University of Virginia, and the Harold Lamport Award of the American Physiology Society Cardiovascular Section.

Michael F. Mahoney is chief executive officer of Boston Scientific Corporation and chairman of the company’s board of directors. Boston Scientific is a global medical technology leader with more than $8 billion in annual revenue and commercial representation in more than 125 countries. Under Mahoney’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 25,000 global employees reaches 22 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, cardiac rhythm management, endoscopy, neuromodulation and urology and women’s health. Mahoney joined Boston Scientific in 2011 as president, and also became chief executive officer and a member of the board of directors in 2012. He was elected chairman in 2016. Since joining Boston Scientific, Mahoney has focused the company on addressing the needs of the evolving health care landscape by driving improvements to patient outcomes and increasing health care economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value for its shareholders.

Mahoney’s career spans more than 25 years of success in building market-leading medical devices, capital equipment and health care IT businesses. Prior to Boston Scientific, he served as worldwide chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson, where he oversaw seven franchises and 50,000 employees. Previously, he served as worldwide group chairman of Johnson & Johnson’s DePuy orthopaedics and neurosciences business, where he drove growth through product innovation, acquisitions and market expansion into China and India.

Prior to joining DePuy, Mahoney was president and chief executive officer of Global Healthcare Exchange (GHX), a joint venture between Johnson & Johnson, General Electric and three other leaders in the medical device, hospital and technology industries. For the first 12 years of his career, Mahoney advanced through a series of leadership roles at General Electric Medical Systems, including general manager of the company’s health care information technology business.

Mahoney serves on the board of directors of Baxter International and the American Heart Association Leadership Council. He earned a B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.
Jonathan Goldman, M.D., M.B.A., has been chief executive officer of Aptuit since 2013. Aptuit is a pharmaceutical services company that delivers early to mid-phase drug development solutions.

Prior to joining Aptuit, Dr. Goldman held several executive positions at ICON plc, a leading global contract research organization. He was ICON’s global head of business development for three years and also had senior roles in operations and medical imaging. Prior to his time at ICON, he served for seven years as Chief Medical Officer at Point Biomedical, a development-stage biopharmaceutical company responsible for discovering and developing microsphere-based pharmaceuticals.

Since 2000, Dr. Goldman also has been associate clinical professor of medicine in the Division of Cardiology at the University of California, San Francisco. In 2015, he accepted a nomination to join the Columbia University Healthcare Advisory Board and now serves on the board with other health care thought leaders and executives from leading pharmaceutical and health care companies.

Dr. Goldman has authored more than 100 scientific publications and has fellowships with a number of prominent medical societies, including the American College of Cardiology, the American Heart Association and the Royal College of Physicians in the United Kingdom.